JP2022541911A - バイオコンジュゲートグリコシル化の定量化 - Google Patents
バイオコンジュゲートグリコシル化の定量化 Download PDFInfo
- Publication number
- JP2022541911A JP2022541911A JP2022503918A JP2022503918A JP2022541911A JP 2022541911 A JP2022541911 A JP 2022541911A JP 2022503918 A JP2022503918 A JP 2022503918A JP 2022503918 A JP2022503918 A JP 2022503918A JP 2022541911 A JP2022541911 A JP 2022541911A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- carrier protein
- modified
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- General Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19187963.4A EP3770269A1 (en) | 2019-07-23 | 2019-07-23 | Quantification of bioconjugate glycosylation |
| EP19187963.4 | 2019-07-23 | ||
| PCT/EP2020/070595 WO2021013854A1 (en) | 2019-07-23 | 2020-07-21 | Quantification of bioconjugate glycosylation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022541911A true JP2022541911A (ja) | 2022-09-28 |
| JP2022541911A5 JP2022541911A5 (cg-RX-API-DMAC7.html) | 2023-07-07 |
Family
ID=67438602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022503918A Pending JP2022541911A (ja) | 2019-07-23 | 2020-07-21 | バイオコンジュゲートグリコシル化の定量化 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220257751A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3770269A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022541911A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114302890A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022001034A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3147700A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022000880A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021013854A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022083585A1 (zh) * | 2020-10-20 | 2022-04-28 | 上海瑞宙生物科技有限公司 | 一种蛋白多糖结合物及其应用 |
| EP4409035A4 (en) * | 2021-09-30 | 2026-01-07 | Venn Biosciences Corp | SYSTEMS AND METHODS FOR DETERMINING GLYCOPEPTIDE CONCENTRATION, DETERMINING STANDARDIZED ABUNDANCE, AND PREPARING SAMPLES FOR LC/MS |
| WO2025172892A1 (en) * | 2024-02-16 | 2025-08-21 | Glaxosmithkline Biologicals Sa | Modified proteins and methods |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008539743A (ja) * | 2005-05-11 | 2008-11-20 | アイトヘネーシシェ テフニーシェ ホフシューレ チューリッヒ | 原核細胞由来の組み換えn−グリコシル化タンパク質 |
| JP2014526449A (ja) * | 2011-09-06 | 2014-10-06 | グリコヴァキシン アーゲー | 原核細胞において製造されるバイオコンジュゲートワクチン |
| WO2019121924A1 (en) * | 2017-12-21 | 2019-06-27 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| WO2019121926A1 (en) * | 2017-12-21 | 2019-06-27 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| KR100310510B1 (ko) | 1993-03-23 | 2002-07-04 | 장 스테판느 | 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물 |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
| DK1481057T3 (da) | 2002-03-07 | 2006-05-15 | Eidgenoess Tech Hochschule | System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært |
| ATE539079T1 (de) | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
| CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| SI2257307T1 (sl) | 2008-02-20 | 2018-09-28 | Glaxosmithkline Biologicals S.A. | Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic |
| US20110189223A1 (en) | 2008-04-16 | 2011-08-04 | Glaxosmithkline Biologicals S.A. | Vaccine |
| KR20110009157A (ko) | 2008-04-16 | 2011-01-27 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
| JP2012533285A (ja) | 2009-07-17 | 2012-12-27 | オーシャン ハーベスト テクノロジー (カナダ) インコーポレイテッド | 魚用飼料中の合成添加物を置換する、天然かつ持続可能な海藻配合物 |
| NO2501406T3 (cg-RX-API-DMAC7.html) | 2009-11-19 | 2018-05-19 | ||
| WO2011138361A1 (en) | 2010-05-06 | 2011-11-10 | Glycovaxyn | Capsular gram-positive bacteria bioconjugate vaccines |
| WO2014037585A1 (en) | 2012-09-10 | 2014-03-13 | Glycovaxyn Ag | Bioconjugates comprising modified antigens and uses thereof |
| KR20150068998A (ko) | 2012-10-12 | 2015-06-22 | 글리코박신 아게 | 숙주 세포 변형 방법 |
| EP2917351B1 (en) | 2012-11-07 | 2018-12-19 | GlaxoSmithKline Biologicals S.A. | Production of recombinant vaccine in e. coli by enzymatic conjugation |
| AR104469A1 (es) | 2014-08-08 | 2017-07-26 | Glycovaxyn Ag | Células huésped modificadas para su uso en producción de bioconjugados |
| SI3240895T1 (sl) | 2014-12-30 | 2022-04-29 | Glaxosmithkline Biologicals S.A. | Sestavki in postopki za glikozilacijo proteinov |
| GB201518668D0 (en) * | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
-
2019
- 2019-07-23 EP EP19187963.4A patent/EP3770269A1/en active Pending
-
2020
- 2020-07-21 CA CA3147700A patent/CA3147700A1/en active Pending
- 2020-07-21 JP JP2022503918A patent/JP2022541911A/ja active Pending
- 2020-07-21 CN CN202080060466.4A patent/CN114302890A/zh active Pending
- 2020-07-21 MX MX2022000880A patent/MX2022000880A/es unknown
- 2020-07-21 BR BR112022001034A patent/BR112022001034A2/pt not_active Application Discontinuation
- 2020-07-21 US US17/628,667 patent/US20220257751A1/en active Pending
- 2020-07-21 EP EP20740641.4A patent/EP4004224A1/en active Pending
- 2020-07-21 WO PCT/EP2020/070595 patent/WO2021013854A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008539743A (ja) * | 2005-05-11 | 2008-11-20 | アイトヘネーシシェ テフニーシェ ホフシューレ チューリッヒ | 原核細胞由来の組み換えn−グリコシル化タンパク質 |
| JP2014526449A (ja) * | 2011-09-06 | 2014-10-06 | グリコヴァキシン アーゲー | 原核細胞において製造されるバイオコンジュゲートワクチン |
| WO2019121924A1 (en) * | 2017-12-21 | 2019-06-27 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| WO2019121926A1 (en) * | 2017-12-21 | 2019-06-27 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220257751A1 (en) | 2022-08-18 |
| CN114302890A (zh) | 2022-04-08 |
| MX2022000880A (es) | 2022-05-02 |
| CA3147700A1 (en) | 2021-01-28 |
| BR112022001034A2 (pt) | 2022-05-24 |
| EP3770269A1 (en) | 2021-01-27 |
| EP4004224A1 (en) | 2022-06-01 |
| WO2021013854A1 (en) | 2021-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7847091B2 (ja) | 肺炎桿菌o抗原ワクチン | |
| EP2142660B1 (en) | Methods and systems for o-glycosylating proteins | |
| JP7551618B2 (ja) | O-結合型グリコシル化のための修飾キャリアタンパク質 | |
| JP6682451B2 (ja) | 改変型宿主細胞およびその使用 | |
| CN104902931A (zh) | 包含修饰的抗原的生物缀合物及其用途 | |
| US20240262870A1 (en) | Glycosylated comp pilin variants, methods of making and uses thereof | |
| JP2014526449A (ja) | 原核細胞において製造されるバイオコンジュゲートワクチン | |
| AU2019404924B2 (en) | O-linked glycosylation recognition motifs | |
| CN111801343A (zh) | 免疫原性组合物 | |
| KR20230164108A (ko) | E. coli O18 생물접합체의 생산 | |
| US20220257751A1 (en) | Quantification of bioconjugate glycosylation | |
| CN111741765A (zh) | 免疫原性组合物 | |
| WO2024175620A1 (en) | Immunogenic composition | |
| JP2024517754A (ja) | O-結合型グリコシル化に十分な最小シークオン | |
| JP2023530154A (ja) | 赤痢菌4価(Shigella4V)バイオコンジュゲート | |
| CN121693343A (zh) | 经修饰的蛋白质 | |
| KR20260051063A (ko) | 변형된 단백질 | |
| EA047805B1 (ru) | Получение биоконъюгатов e.coli o18 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230629 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230629 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240611 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240902 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250107 |